These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

360 related items for PubMed ID: 20105399

  • 21. Serotonin syndrome in the elderly after antidepressive monotherapy.
    Fischer P.
    J Clin Psychopharmacol; 1995 Dec; 15(6):440-2. PubMed ID: 8748434
    [No Abstract] [Full Text] [Related]

  • 22. Serotonin-norepinephrine reuptake inhibitor therapy in late-life depression is associated with increased marker of bone resorption.
    Shea ML, Garfield LD, Teitelbaum S, Civitelli R, Mulsant BH, Reynolds CF, Dixon D, Doré P, Lenze EJ.
    Osteoporos Int; 2013 May; 24(5):1741-9. PubMed ID: 23358607
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Venlafaxine-induced hyponatremia.
    Gupta AK, Saravay SM.
    J Clin Psychopharmacol; 1997 Jun; 17(3):223-5. PubMed ID: 9169969
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Selective serotonin reuptake inhibitor. Discontinuation syndrome.
    Finfgeld DL.
    J Psychosoc Nurs Ment Health Serv; 2002 Dec; 40(12):14-8. PubMed ID: 12491870
    [Abstract] [Full Text] [Related]

  • 29. Adverse events after the abrupt discontinuation of paroxetine.
    Dominguez RA, Goodnick PJ.
    Pharmacotherapy; 1995 Dec; 15(6):778-80. PubMed ID: 8602387
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Possible venlafaxine withdrawal syndrome.
    Farah A, Lauer TE.
    Am J Psychiatry; 1996 Apr; 153(4):576. PubMed ID: 8599410
    [No Abstract] [Full Text] [Related]

  • 33. Selective serotonin reuptake inhibitor discontinuation with ECT and withdrawal symptoms.
    Markowitz JS.
    J ECT; 1998 Mar; 14(1):55. PubMed ID: 9661096
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Antidepressant options: venlafaxine in perspective.
    Thase ME.
    J Clin Psychopharmacol; 1996 Jun; 16(3 Suppl 2):10S-18S; discussion 18S-20S. PubMed ID: 8784644
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome.
    Gitlin MJ.
    J Clin Psychopharmacol; 1997 Feb; 17(1):66-7. PubMed ID: 9004070
    [No Abstract] [Full Text] [Related]

  • 39. Neurodevelopment of children following prenatal exposure to venlafaxine, selective serotonin reuptake inhibitors, or untreated maternal depression.
    Nulman I, Koren G, Rovet J, Barrera M, Pulver A, Streiner D, Feldman B.
    Am J Psychiatry; 2012 Nov; 169(11):1165-74. PubMed ID: 23128923
    [Abstract] [Full Text] [Related]

  • 40. Emergence of adverse events following discontinuation of treatment with extended-release venlafaxine.
    Fava M, Mulroy R, Alpert J, Nierenberg AA, Rosenbaum JF.
    Am J Psychiatry; 1997 Dec; 154(12):1760-2. PubMed ID: 9396960
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.